A nationwide population-based study of common bile duct stone recurrence after endoscopic stone removal in Korea

Byung Kyu Park1, Jeong Hun Seo2, Han Ho Jeon1

  • 1Division of Gastroenterology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea.

Insights

Patients undergoing endoscopic common bile duct (CBD) stone removal have a low first recurrence rate but high subsequent rates. Cholecystectomy is recommended for younger patients with gallbladder stones to reduce CBD stone recurrence.

Area of Science:

  • Gastroenterology
  • Hepatobiliary Surgery

Background:

  • Lack of consensus exists regarding follow-up protocols for patients after endoscopic common bile duct (CBD) stone removal.
  • The necessity of cholecystectomy in patients with gallbladder (GB) stones remains debated, particularly concerning its impact on CBD stone recurrence.

Purpose of the Study:

  • To investigate the recurrence rate of CBD stones after endoscopic removal.
  • To evaluate the impact of cholecystectomy on the recurrence rate of CBD stones.

Main Methods:

  • A population-based study utilizing the National Health Insurance database.
  • Inclusion criteria: patients diagnosed with CBD stones and registered for endoscopic stone removal.
  • Outcomes assessed: primary - CBD stone recurrence rate; secondary - difference in recurrence rate based on cholecystectomy status.

Main Results:

  • Over 46,000 patients were analyzed with a mean follow-up of 4.2 years.
  • The cumulative first CBD stone recurrence rate was 11.3%, with significantly higher second (23.4%) and third (33.4%) recurrence rates.
  • The recurrence rate was substantially higher in patients who did not undergo cholecystectomy compared to those who did (p < 0.0001), with increased risk in younger age groups.

Conclusions:

  • Routine follow-up is not advised for first-time endoscopic CBD stone removal patients, but is recommended for those with recurrent stones.
  • Cholecystectomy is recommended for patients with GB stones younger than 70 years to mitigate CBD stone recurrence risk.
Abstract